A carregar...
CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...
Na minha lista:
| Publicado no: | Oncol Rev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PAGEPress Publications, Pavia, Italy
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683209/ https://ncbi.nlm.nih.gov/pubmed/31452841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/oncol.2019.416 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|